AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00648076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depakote ER® Tablets 500 mg
Description: 500mg, single dose fed
Study NCT04485962 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibroblasts and keratinocytes
Description: Autologous cultured fibroblasts and keratinocytes~For PR: The name  fibroblasts and keratinocytes is exactly the name of the cell product registered by our ministry of health. There is no trade or international name.
Study NCT02545673 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced linkage to care
Study NCT02545673 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care plus
Study NCT01243450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin
Description: Treatment of acne
Study NCT01243450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: treatment of acne
Study NCT03516318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART Connections
Description: SMART Connections: Trained facilitators will deliver key informational messages and moderate online group discussions. The informational messages have been developed from key messages identified in each of the Positive Connections curriculum sessions. Each SMART Connections group will consist of approximately 15 to 20 YLHIV. Each online support group will begin with one in-person group meeting with the facilitator. During this meeting, participants meet one another and the facilitators. Facilitators will describe the intervention and set ground rules for participation. Ground rules will be discussed and accepted by the group members, but at a minimum, group members will be advised not to talk about what is discussed in the online group with people outside of the group.
Study NCT00788554 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lichtenstein procedure
Description: open surgical procedure for inguinal hernia correction
Study NCT00788554 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TEP
Description: Total Exta Peritoneal procedure for inguinal hernia correction
Study NCT00237744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotics training for shoulder elbow.
Description: training utilizing a robot to assist with movement practice
Study NCT00237744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surface Functional Neuromuscular Stimulation
Description: training utilizing FNS to assist with movement practice
Study NCT00237744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole arm motor learning
Description: intervention utilizing motor learning training principles to perform part and whole task practice of meaningful everyday functional tasks.
Study NCT03904472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based CBTI
Description: Sessions comprise a range of cognitive and behavioral techniques and psychoeducation including sleep hygiene. During the intervention period the participant will complete daily online sleep diaries. Additionally, participants will be asked to complete multiple questionnaires.
Study NCT02176889 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactospore
Description: Bacillus coagulans MTCC 5856
Study NCT02176889 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01793792 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LVIS™ and LVIS™ Jr
Description: The LVIS Device is intended for use with embolization coils for the treatment of wide neck, intracranial aneurysms.
Study NCT00283686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg
Study NCT00283686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lisinopril
Description: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg
Study NCT00283686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants
Study NCT00283686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants
Study NCT00283686 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Blood Pressure Control
Description: Achieve standard blood pressure control of 120-130/70-80 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator
Study NCT00283686 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Blood Pressure Control
Description: Achieve standard blood pressure control of 120-130/70-80 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator
Study NCT00283686 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Blood Pressure Control
Description: Achieve low blood pressure control of 95-110/60-75 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator
Study NCT05916508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.454% stannous fluoride
Description: Brush two times daily
Study NCT05916508 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0.76% sodium monofluorophosphate
Description: Brush two times daily
Study NCT05916508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride AM and 0.76% sodium monofluorophosphate PM
Description: Brush two times daily
Study NCT02011438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UTalk
Description: Prevention intervention delivered in group format adapted from IPT-AST, for adolescents who experience peer victimization and who are at risk for developing social anxiety and depression.
Study NCT02116465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa Carbidopa immediate release tablets
Description: oral administration
Study NCT01775891 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pilsicainide
Description: The dose of pilsicainide will be 50mg tid PO. Pilsicainide will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
Study NCT01775891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pilsicainide
Description: The dose of pilsicainide will be 50mg tid PO. Pilsicainide will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
Study NCT01775891 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: other class IC antiarrhythmic drug
Description: Other class IC antiarrhythmic drug that they had been taking before catheter ablation will be administrated.(flecainide 100mg bid PO or propafenone 225mg tid) Antiarrhythmic drug will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
Study NCT00283686 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low Blood Pressure Control
Description: Achieve low blood pressure control of 95-110/60-75 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator
Study NCT03486808 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DLPFC stimulation
Description: stimulating left dorsolateral prefrontal cortex with transcranial direct current stimulation for 30 minutes
Study NCT03486808 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DLPFC stimulation
Description: stimulating left dorsolateral prefrontal cortex with transcranial direct current stimulation for 30 minutes
Study NCT03486808 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: sham stimulation over both left inferior frontal cortex and dorsolateral prefrontal cortex
Study NCT01775891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: other class IC antiarrhythmic drug
Description: Other class IC antiarrhythmic drug that they had been taking before catheter ablation will be administrated.(flecainide 100mg bid PO or propafenone 225mg tid) Antiarrhythmic drug will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
Study NCT02486224 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kona Deep
Description: Subjects will receive Kona Deep post exercise
Study NCT04611048 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Thermal QST (cold and warm detection, heat pain) with the psi method
Description: The Psi algorithm is a method using Bayesian statistics to determine not only the threshold but also the slope of the psychometric function (relationship between the intensity of a stimulus and its detection probability; Kingdom \& Prins, 2010). The algorithm selects the next stimulus intensity to be the most informative on the parameters of interest, based on the prior probability density. After each stimulation, the subject will be asked if he/she felt it (as painful) or not. Based on that answer, a posterior probability density is computed. This posterior is then used as prior for the next stimulation. The stimuli will last maximum 1 s and temperature will be kept between 0°C and 60°C.
Study NCT02486224 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Spring Water
Description: Subjects will receive Spring Water post exercise
Study NCT02486224 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sports Drink
Description: Subjects will receive Sports Drink post exercise
Study NCT02998242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Study NCT02998242 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT to symptomatic bony metastatic bony site(s)
Study NCT02998242 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT to symptomatic bony metastatic bony site(s)
Study NCT02585895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection once every 2 weeks
Study NCT02585895 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab
Description: Administered by subcutaneous injection once every 2 weeks
Study NCT02585895 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low-density Lipoprotein Cholesterol (LDL-C) Apheresis
Description: Participants received apheresis for LDL-C according the their physician's prescription and local custom.
Study NCT03181360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenecteplase
Description: Single dose intravenous injection of recombinant fibrin-specific tissue plasminogen activator (tenecteplase) 0.25 mg (200 IU) per kg body weight up to a maximum of 25 mg (5000 IU), given as a bolus over approx. 10 seconds.
Study NCT03181360 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Best standard treatment
Study NCT01060228 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: paliperidone ER
Description: 1 tablet of 500 mg once daily on Day 1 and Day 15
Study NCT01060228 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: divalproex sodium ER
Description: 2 tablets of 500 mg once daily from Days 5 through 18
Study NCT01990235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREPARE Intervention
Description: At week 1, 3, 6, and 12 months, interviews (telephone or in person based on preference) by blinded staff will assess engagement in advance care planning(ACP), self-efficacy with ACP, and activation in and satisfaction with decision making. Blinded telephone interviews will also assess surrogate reports of patient engagement in ACP.
Study NCT00644098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soluble fibre complex and medium chain triglycerides
Study NCT03411655 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu Aura GainTM
Description: Time and success rate
Study NCT03411655 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu® Aura-ITM
Description: Time and success rate
Study NCT03822299 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: healthy feces microbiota
Description: Suspension of healthy feces microbiota in sterile saline solution
Study NCT00695331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Titrated Misoprostol Solution
Study NCT00695331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Titrated Intravenous Oxytocin
Study NCT03125304 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: acupuncture
Description: They will be treated seven days before expected menstrual onset with once a day and three times a week for therapy. During the menstrual period,they will be treated everyday when they are having pain.Every treatment lasts 30 minutes. The trial period will consist of three menstrual cycles of treatment and three menstrual cycles in the follow-up period.
Study NCT03125304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: They will be treated seven days before expected menstrual onset with once a day and three times a week for therapy. During the menstrual period,they will be treated everyday when they are having pain.Every treatment lasts 30 minutes. The trial period will consist of three menstrual cycles of treatment and three menstrual cycles in the follow-up period.
Study NCT02264067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talsaclidine
Study NCT02264067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03443960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL 5.6 mg
Description: Subjects randomly assigned to this treatment will place 2 tablets simultaneously under the tongue until dissolved, and not to crush or chew them.
Study NCT03443960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amrix 30 mg
Description: Subjects randomly assigned to this treatment will swallow 1 capsules with a cup of water, and not to crush or chew it.
Study NCT01257295 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: control: no fiber addition
Description: liquid breakfast without addition of fiber
Study NCT01257295 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: breakfast with low viscous, low gelling pectin
Description: 10g of low viscous, low gelling pectin dissolved in a liquid breakfast
Study NCT01257295 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: high viscous, low gelling pectin
Description: 10g of high viscous, low gelling pectin dissolved in a liquid breakfast
Study NCT01257295 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low viscous, high gelling pectin
Description: 10g of low viscous, high gelling pectin dissolved in a liquid breakfast
Study NCT01257295 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: high viscous, high gelling pectin
Description: 10g of high viscous, high gelling pectin dissolved in a liquid breakfast
Study NCT01257295 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: pectin supplement
Description: 10g of high viscous, high gelling pectin provided as a dietary supplement, a liquid breakfast is served seperately
Study NCT02630667 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SLOW Carbohydrate
Description: Treatment consists of a carbohydrate blend designed to elicit a slow postprandial glycemic response
Study NCT02630667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SLOW Carbohydrate
Description: Treatment consists of a carbohydrate blend designed to elicit a slow postprandial glycemic response
Study NCT02630667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MEDIUM Carbohydrate
Description: Treatment consists of only one carbohydrate source designed to elicit a medium/moderate postprandial glycemic response
Study NCT02630667 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MEDIUM Carbohydrate
Description: Treatment consists of only one carbohydrate source designed to elicit a medium/moderate postprandial glycemic response
Study NCT02630667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAST Carbohydrate
Description: Treatment consists of only one carbohydrate source designed to elicit a fast postprandial glycemic response
Study NCT02630667 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: FAST Carbohydrate
Description: Treatment consists of only one carbohydrate source designed to elicit a fast postprandial glycemic response
Study NCT03131648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
Study NCT03131648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains the same excipients, in the same concentration only lacking tralokinumab
Study NCT03131648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo contains the same excipients, in the same concentration only lacking tralokinumab
Study NCT01141192 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3, cholecalciferol
Description: 1 gelcap of 50,000 IU vitamin D3 plus 2 gelcaps of 5,000 IU vitamin D3 each; a total of 60,000 IU vitamin D3 dosed four weeks apart at weeks 0, 4, 8, and 12 of the 16 week study.
Study NCT01141192 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Inactive comparator
Description: The inactive comparator dose provided was identical in appearance to the active comparator but contained no vitamin D3
Study NCT00563784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg by mouth daily for 7 Weeks
Study NCT00563784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 2 AUC by vein weekly for 7 Weeks
Study NCT00563784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 45 mg/m\^2 by vein weekly for 7 Weeks
Study NCT00563784 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 63 GY/35 fractions for 7 weeks (+/- 5 days)
Study NCT03966976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG monitoring & record
Description: This is a mobile ECG recorder that not only records short portions of ECG on one or three leads, but also stores, processes and transmits their data to facilitate the diagnosis and to confirm the occurrence of AF arrhythmia episodes by the physician.
Study NCT04611048 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neurological examination
Description: A standardized neurological examination will be performed to assess all the items included in the Utah Early Neuropathy Scale (UENS ) (Singleton et al., 2008) and the Toronto Clinical Neuropathy Score (TCNS)(Perkins, Olaleye, Zinman, \& Bril, 2001). This will include: questions about symptoms (presence or absence of foot pain, numbness, tingling, weakness, imbalance and upper limb symptoms); evaluation of knees and ankles deep tendon reflexes; evaluation of pinprick, temperature, light touch, vibration (128 Hz tuning fork) compared to that of an unaffected sites (e.g., sternum); position sensation in the big toes; mapping of pinprick sensitivity in the lower leg; and evaluation of the active extension of the big toes. Pinprick evaluation will be performed using a disposable pin designed for that purpose (Medipin, The United-Kingdom).
Study NCT03966976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional follow-up
Description: Conventional follow-up
Study NCT00644098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: cellulose and soybean oil
Study NCT02328547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation capsules
Description: Fecal microbiota transplantation capsules contain extensively screened donor stool and are prepared by OpenBiome, Medford, MA.
Study NCT02328547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Placebo capsules prepared by OpenBiome, Medford, MA
Study NCT02766387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of the correlation between walking speed in the 6MWT and in 2MWT, and the walking speed observed in the continuous 2km walk test and in the 10 meters walk test.